FTC Workshop to Revisit Competition Issues Regarding Follow-On Biologics

Five years ago, the Federal Trade Commission (FTC) waded into the debate regarding the benefits and potential competition issues posed by the introduction of "follow-on biologics." Now, some three years after Congress provided a pathway for approval...
By: Wilson Sonsini Goodrich & Rosati

Wilson Sonsini Goodrich & Rosati